However, it is unexpected to observe reduced expression of signature genes IFNG, CCL3, CLL4, and GZMB in TH1/17 cells in MS vs. healthy controls, especially the reduced expression of IFNG. Natalizumab, a humanized monoclonal antibody targeting α4 integrin used in the treatment of MS, functions by preventing immune cells from crossing the blood–brain barrier45. This evidence concerns the gene IFNG and myeloid sarcoma.